TransRAMPART
Research type
Research Study
Full title
Translational Renal Adjuvant MultiPle Arm Randomised Trial (TransRAMPART)
IRAS ID
283098
Contact name
Ben Smith
Contact email
Sponsor organisation
University College London
ISRCTN Number
ISRCTN53348826
Clinicaltrials.gov Identifier
Duration of Study in the UK
9 years, 0 months, 0 days
Research summary
Renal cell carcinoma is a type of kidney cancer that starts from the kidneys. It is the 8th most common cancer in the UK and an increase of new cases of 2% has been seen in the last twenty years. About half of the new cases of kidney cancer are among people aged 70 and above.
Patients whose disease has not spread outside the kidneys typically have surgery to remove a part or all of their kidney (called a partial or radical nephrectomy). After surgery, patients are seen by their doctor with regular check-ups to look for signs of the cancer coming back or spreading to other parts of the body; this is generally called ‘active monitoring’ or ‘active surveillance’. Unfortunately, it is estimated that the cancer will return in 30-40% of the patients who have undergone surgery.
Many clinical studies have been carried out to find if a new treatment after surgery might slow the cancer coming back or prevent it from coming back altogether. However, to date no treatment is available. RAMPART is a study looking at two new immunotherapy treatments (durvalumab and tremelimumab) that have shown a benefit in other cancer types.
TransRAMPART is a translational research study being run within the RAMPART clinical trial. Translational research is carried out in the laboratory on biological samples that our patients provide. By biological samples we mean samples of tumour, blood and urine. In TransRAMPART study we will carry out research on these samples to gain a better understanding of kidney cancer and how people respond to treatment with the class of medication (immune checkpoint inhibitors) our patients will be taking in RAMPART.
REC name
London - Riverside Research Ethics Committee
REC reference
20/PR/0459
Date of REC Opinion
13 Oct 2020
REC opinion
Favourable Opinion